Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world\'s preeminent experts in hearing loss, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and is headquartered in Cambridge, Mass.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/15 | $52,000,000 | Series A |
SR One | undisclosed |
| 06/19/18 | $55,000,000 | Series C |
Foresite Capital Longevity Fund Regeneron Pharmaceuticals S-Cubed Capital Schroder Adveq SR One Third Rock Ventures | undisclosed |
| 11/09/20 | $82,000,000 | Series D |
BlackRock Casdin Capital Foresite Capital GV Janus Henderson Investors OrbiMed Advisors  S-Cubed Capital Samsara BioCapital Sobrato Organization SR One Surveyor Capital Third Rock Ventures | undisclosed |
